Alteron Therapeutics

Alteron Therapeutics is a private, preclinical-stage biotechnology company focused on discovering and developing precision therapies targeting TDP-43 proteinopathy, a root cause of several neurodegenerative diseases including ALS, Alzheimer's disease, and frontotemporal lobar degeneration (FTLD), as well as cystic fibrosis. The company's core innovation is the ALTA series of small molecule drugs designed to inhibit TDP-43's toxic nucleic acid binding by targeting its guanine pocket. Founded in the late 2010s and incubated at Western Michigan University, Alteron is advancing its lead candidate, ALTA-808, towards IND-enabling studies with the goal of rapidly reversing symptoms in debilitating conditions.

A platform for discovering small molecule inhibitors that precisely target the guanine pocket of TDP-43 protein, inhibiting its toxic nucleic acid binding to address the root cause of multiple neurodegenerative diseases and cystic fibrosis.

Alteron faces indirect competition from numerous companies developing therapies for ALS, Alzheimer's, and CF, but has few direct competitors targeting TDP-43 inhibition with small molecules. Its main differentiation is a precision root-cause approach against a common pathological driver, contrasted with competitors focusing on downstream symptoms or singular genetic targets.